Key result
Upstream UFH yields ~47% higher rates of pre-PCI TIMI 2-3 flow without increasing bleeding.
Why the study?
Unfractionated heparin has been proposed to enhance pre-procedural coronary reperfusion in STEMI, but the efficacy of UFH pre-treatment in patients undergoing primary PCI remains unclear.
Does pre-treatment with unfractionated heparin improve coronary reperfusion and clinical outcomes compared with standard care in STEMI patients undergoing primary PCI?
Meta-Analysis (n=12,288)
Randomized controlled trials
Does pre-treatment with unfractionated heparin improve coronary reperfusion and clinical outcomes compared with standard care in STEMI patients undergoing primary PCI?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Our analysis brought together evidence from 5 randomized controlled trials, involving 12,288 participants. The results showed significantly better pre-PCI coronary reperfusion with upstream unfractionated heparin, without a significant increase in major bleeding or all-cause mortality. The findings add to the existing evidence on early anticoagulation in STEMI management and reinforce the role of evidence-based approaches in clinical practice.”
In STEMI patients undergoing primary PCI, unfractionated heparin pre-treatment significantly improves pre-procedural infarct-related artery patency without increasing major bleeding or mortality compared to standard care.
Introduction: Unfractionated heparin (UFH), due to its rapid onset of action and widespread use during primary percutaneous coronary intervention (PPCI), has been proposed as a strategy to enhance pre-procedural coronary reperfusion in patients with ST-segment elevation myocardial infarction (STEMI), in whom PPCI remains the standard reperfusion therapy. Early restoration of infarct-related artery patency before primary PCI improves myocardial perfusion and outcomes. However, the efficacy of UFH pretreatment in STEMI patients undergoing PPCI remains unclear and needs further study. Hypothesis: We sought to determine if pre-treatment with UFH improves coronary reperfusion and clinical outcomes compared with standard care in STEMI patients undergoing primary PCI. Methods: A comprehensive search was performed in PubMed, Embase, Scopus and the Cochrane Library from inception until May 2025. All randomized controlled trials (RCTs) that compared unfractionated heparin pre-treatment to standard care in patients with STEMI undergoing PPCI (PROSPERO CRD420261405363) were included. Data were extracted for angiographic, clinical and safety outcomes. Pooled risk ratios (RR) with 95% confidence intervals were estimated from random-effects models using the I 2 statistical heterogeneity. Results: A total of five RCTs comprising 12,288 participants were included in the analysis. Pre-PCI TIMI flow grade 2-3 or 3 was significantly higher in the UFH group (RR = 1.47, 95% CI: 1.37-1.57; P < 0.01, I 2 = 0%). Post-PCI TIMI flow grade 3 showed a statistically significant but minimal improvement (RR = 1.01, 95% CI 1.00-1.01; P = 0.03; I 2 = 0%). All-cause mortality (RR = 0.90, 95% CI 0.75-1.08; P = 0.25; I 2 = 0%) and major bleeding were not significantly different between groups (RR = 0.98, 95% CI 0.60-1.61; P = 0.94), with no evidence of heterogeneity across studies. Conclusion: In STEMI patients undergoing primary PCI, UFH pre-treatment is associated with improved early coronary reperfusion but does not increase major bleeding or the need for blood transfusion compared to standard care. These results are consistent with a procedural advantage of UFH pre-treatment to improve infarct-related artery patency within modern STEMI networks.
No takes yet. Share an insight, caveat, or question.
Fatima et al. (2026) conducted a meta-analysis in ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) (n=12,288). Upstream unfractionated heparin (UFH) pre-treatment vs. Standard care (routine UFH) was evaluated on Pre-PCI TIMI flow grade 2-3 or 3 (RR 1.47, 95% CI 1.37-1.57, p=<0.01). Upstream UFH pre-treatment increased pre-PCI TIMI flow grade 2-3 or 3 compared to standard care without increasing major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: